For instance, over the years, TRAIL and other ligands against TRAIL-R1/R2 have generated considerable interest, due to the selectivity of these ligands towards cancer cells, with little to no toxicity to noncancerous cells [77], suggesting their usefulness as cancer therapies. Here, TNFRSF10A is linked to cancer.